{"disease":{"id":"histiocytic-neoplasms","name":"histiocytic neoplasms"},"drugs":{"marketed":[{"drug_id":"cobimetinib","indication_name":"Histiocytic Neoplasms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cotellic","generic_name":"cobimetinib","company_name":"Roche","drug_phase":"marketed","molecular_target":"Dual specificity mitogen-activated protein kinase kinase 1","drug_class":"Kinase Inhibitor","quality_score":66,"revenue":"200","mechanism":"Cotellic works by blocking the activity of two proteins, BRAF and MEK, which are involved in the growth and spread of cancer cells."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"cobimetinib","guideline_body":"FDA label","recommendation":"COTELLIC®, as a single agent, is indicated for the treatment of adult patients with histiocytic neoplasms.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}